-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$45.0046.25% Upside
Edgewise Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Edgewise Therapeutics, Inc.?
Edgewise Therapeutics, Inc. has been rated by research analysts at Piper Sandler, RBC Capital, Leerink Partners in the past 90 days.